ADP sensitizes ZL55 cells to the activity of cisplatin.

Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor in which cisplatin therapy is commonly used, although its effectiveness is limited. It follows that research efforts dedicated to identify promising combinations that can synergistically kill cancer cells are needed. Because we recently demonstrated that ADP inhibits the proliferation of ZL55 cells, an MPM‐derived cell line obtained from bioptic samples of asbestos‐exposed patients. Our objective in this study was to investigate the hypothesis that ADP also potentiates the cytotoxic activity of cisplatin. Results show that in ZL55 cells ADP enhanced (a) the cytotoxicity of cisplatin by 12‐fold, (b) the restraint of cell clonogenic potential cisplatin‐mediated, and (c) the number of apoptotic cells. Cisplatin, but not ADP, caused caspases activation; nevertheless, poly(ADP‐ribose) polymerase‐1 was not only cleaved in cisplatin‐treated cells but also in cells treated with ADP alone. Furthermore, ADP, but not cisplatin, decreased mTOR and 6SK phosphorylations. Both ADP and cisplatin increased p53 protein, but ADP was also able to enhance p53 messenger RNA. P53 silencing resulted in a very large decrement of cell death induced by ADP or by cisplatin and reverted ADP effects on mTOR/S6K phosphorylation, suggesting that activated p53 may act as a negative regulator of mTOR. Consistently, the inhibition of mTOR by rapamycin also sensitized cells to cisplatin, and the effects of cisplatin plus rapamycin were identical to those obtained with cisplatin plus ADP. These findings suggest that the combination of ADP and cisplatin may be a promising strategy for the clinical treatment of cisplatin‐resistant MPM. The manuscript investigates the effects of ADP on cisplatin treatment in ZL55 epitheliod malignant mesothelioma cells. We show that the simultaneous addition of ADP enhanced the antiproliferative potency of cisplatin with an additive effect of the anticancer drugs and ADP on ZL55 cell apoptosis. In addition, for the first time, we show that extracellular ADP operates a tumor‐suppressive regulatory program by p53, in which cell‐cycle arrest is made mainly at the transcriptional level, whereas cell growth inhibition is enforced by repression of mTOR pathway. [ABSTRACT FROM AUTHOR]